Aura Biosciences, Inc.
AURA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501796
No open-market purchases or sales by Aura Biosciences, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $677.2M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $796.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +21 vs. previous quarter
- 146
- 13F valueReported value at the end of Q2 2026
- $677.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$106.2M
- No comparable prior period
- Free cash flow, FY2025
- -$85.2M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.5M
- Shares sold short
- Change
- −421.7K
- −3.9% vs. previous
- Days to cover
- 13.67
- At average daily volume
Superinvestors holding AURA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AURA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Aura Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 (view filing) | Jun 16 | Same day | Gibney Anthony SSee Remarks | SSale | −12.8K | $6.42 | −$82.3K | −4.6%265.4K after | |
| May 11, 2026 (view filing)4:16 PM ET | May 7 | 4 days | Matrix Capital Management Company, LP and 1 other10% Owner | SSaleCommon Stock, par value $0.00001 per share (Common Stock) | −6.92M | $5.64 | −$39.0M | −100.0%0 after | |
| Apr 16, 2026 (view filing) | Apr 16 | Same day | Kilroy ConorSee Remarks | SSale | −11.7K | $7.02 | −$82.4K | −5.1%217.8K after | |
| Feb 17, 2026 (view filing) | Feb 17 | Same day | Kilroy ConorSee Remarks | SSale | −12.1K | $5.05 | −$61.0K | −6.7%167.2K after | |
| Feb 17, 2026 (view filing) | Feb 17 | Same day | Plavsic MarkChief Technology Officer | SSale | −15.9K | $5.05 | −$80.2K | −8.1%181.4K after | |
| Feb 17, 2026 (view filing) | Feb 17 | Same day | Hopkins Janet JillChief Medical Officer | SSale | −20.4K | $5.06 | −$103.2K | −8.1%232.3K after | |
| Feb 17, 2026 (view filing) | Feb 17 | Same day | Elazzouzi AmySenior Vice President, Finance | SSale | −8.55K | $5.06 | −$43.3K | −10.2%75.5K after | |
| Feb 17, 2026 (view filing) | Feb 17 | Same day | de los Pinos ElisabetSee Remarks | SSale | −47.6K | $5.06 | −$241.1K | −10.4%409.8K after | |
| Jan 20, 2026 (view filing) | Jan 20 | Same day | Elazzouzi AmySenior Vice President, Finance | SSale | −1.58K | $4.86 | −$7.68K | −1.8%84.1K after | |
| Jan 20, 2026 (view filing) | Jan 20 | Same day | de los Pinos ElisabetSee Remarks | SSale | −16.9K | $4.86 | −$82.3K | −3.6%457.5K after |
Top 10 13F holders, Q2 2026
See all 146 holdersThe largest institutional positions in Aura Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 9,533,333 | $67.7M | 1.63% | +9,533,333 | New |
| Suvretta Capital Management, LLC | 7,206,217 | $51.2M | 1.08% | +2,833,333+64.8% | Added |
| Frazier Life Sciences Management, L.P. | 7,100,000 | $50.4M | 1.10% | +2,000,000+39.2% | Added |
| Long Focus Capital Management, LLC | 5,119,582 | $36.3M | 1.48% | +500,000+10.8% | Added |
| BlackRock, Inc. | 4,707,674 | $33.4M | 0.00% | +1,121,034+31.3% | Added |
| Adage Capital Partners GP, L.L.C. | 4,640,000 | $32.9M | 0.05% | −241,125−4.9% | Reduced |
| Caligan Partners LP | 4,298,248 | $30.5M | 1.47% | +4,068,384+1,769.9% | Added |
| Vanguard Capital Management LLC | 4,100,342 | $29.1M | 0.00% | +1,856,514+82.7% | Added |
| FCPM III Services B.V. | 4,053,775 | $28.8M | 3.84% | +4,053,775 | New |
| OrbiMed Advisors LLC | 3,333,333 | $23.7M | 0.45% | +3,333,333 | New |
Holders of 5% or more of AURA
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Aura Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 13G | 9.90%9.53M shares | New | May 12, 20261 filing | May 12, 2026 | SEC |
| Adage Capital Management, L.P. | 13G/A | 8.44%9.10M shares | – | Nov 12, 20242 filings | Aug 12, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 7.60%4.70M shares | +1.50 ppfrom 6.10% | Apr 11, 20252 filings | Aug 13, 2025 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.60%5.81M shares | −0.70 ppfrom 6.30% | May 23, 20254 filings | Aug 14, 2026 | SEC |
| ForGrowth III PA B.V. | 13G | 5.10%5.25M shares | New | Oct 1, 20261 filing | Oct 1, 2026 | SEC |